Greenwich LifeSciences (GLSI) Liabilities and Shareholders Equity (2019 - 2025)

Greenwich LifeSciences' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $6.2 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 50.91% year-over-year to $6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.9 million (down 30.0% YoY) and the FY2025 annual result came in at $6.2 million, up 50.91% from the prior year.
• Liabilities and Shareholders Equity was $6.2 million for Q4 2025 at Greenwich LifeSciences, up from $3.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $30.4 million in Q1 2021 and bottomed at $2.8 million in Q1 2025.
• A 5-year average of $13.0 million and a median of $10.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 360.94% — and 2025, when it plunged 56.77%.
• Greenwich LifeSciences' Liabilities and Shareholders Equity stood at $27.2 million in 2021, then slumped by 50.48% to $13.5 million in 2022, then tumbled by 48.1% to $7.0 million in 2023, then tumbled by 41.47% to $4.1 million in 2024, then surged by 50.91% to $6.2 million in 2025.
• Business Quant data shows GLSI's Liabilities and Shareholders Equity at $6.2 million in Q4 2025, $3.8 million in Q3 2025, and $3.1 million in Q2 2025.